Theravance Biopharma (TBPH) Cash from Discontinued Operations (2021 - 2022)
Theravance Biopharma (TBPH) reported Cash from Discontinued Operations of 178968000.0 for Q4 2022, down 6455.4% year-over-year from 2816000.0 in Q4 2021, and down 3335.75% quarter-over-quarter from 5209000.0 in Q3 2022.
Theravance Biopharma (TBPH) Cash from Discontinued Operations (2021 - 2022) Analysis & Trends
Theravance Biopharma (TBPH) has 2 years of Cash from Discontinued Operations data on file, last reported at 178968000.0 in Q4 2022.
- Cash from Discontinued Operations for Q4 2022 came in at 178968000.0, down 6455.4% year-over-year; the trailing twelve-month figure through Dec 2022 was 184566000.0 (changed N/A YoY), and the FY2022 annual result was 184566000.0, down 761.12% from the prior year.
- Cash from Discontinued Operations fell to 178968000.0 in Q4 2022 per TBPH's latest filing, from 5209000.0 in the prior quarter.
- Over five years, Cash from Discontinued Operations peaked at 2816000.0 in Q4 2021 and troughed at 178968000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -59.14 Mn |
| 10 | Theravance Biopharma | 846.10 Mn | 451.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -178.97 Mn |
| Dec 31, 2022 | -178.97 Mn |
| Sep 30, 2022 | -5.21 Mn |
| Sep 30, 2022 | -5.21 Mn |
| Jun 30, 2022 | -1.00 Mn |
| Jun 30, 2022 | -1.00 Mn |
| Mar 31, 2022 | 615,000.00 |
| Mar 31, 2022 | 615,000.00 |
| Dec 31, 2021 | 2.82 Mn |
| Dec 31, 2021 | 2.82 Mn |